Tag: <span>Mesothelioma News</span>

IMPRINT Mesothelioma Treatment Boosts Radiation Therapy

Doctors confirmed a novel radiation procedure can be combined safely and effectively with aggressive lung-sparing surgery to improve survival time and quality of life for patients with mesothelioma. After a decade of refinement, a small number of mesothelioma specialty centers now are using intensity-modulated pleural radiation therapy (IMPRINT) as part of the recent advancements in…

The post IMPRINT Mesothelioma Treatment Boosts Radiation Therapy appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

IMPRINT Mesothelioma Treatment Boosts Radiation Therapy

Doctors confirmed a novel radiation procedure can be combined safely and effectively with aggressive lung-sparing surgery to improve survival time and quality of life for patients with mesothelioma. After a decade of refinement, a small number of mesothelioma specialty centers now are using intensity-modulated pleural radiation therapy (IMPRINT) as part of the recent advancements in…

The post IMPRINT Mesothelioma Treatment Boosts Radiation Therapy appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Workers angry over WA asbestos scandal

A worker exposed to asbestos at Perth’s new children’s hospital this week says building giant John Holland has provided no medical help as the government announced an independent investigation into the scandal. It is not the most hazardous asbestos but is banned in Australia and when inhaled can cause deadly diseases such as lung cancer, mesothelioma or asbestosis.

Dying woman’s battle to keep kids safe from the asbestos that caused her cancer

Sue Stephens was exposed to the deadly substance during 30 years of classroom teaching – and her first thought was to spare her pupils the same fate A primary school teacher for 30 years, Sue was exposed to the deadly fibres in the classroom. But her f…

Expanding the potential of existing cancer therapies: an interview with Dr Mark Rutstein

When people think about the fight against cancer they often focus on the development of new therapies, but why is it important to consider existing therapies too? Cancer remains a leading cause of death worldwide, and the global cancer burden is expect…

Redditch man died as a result of an industrial disease, a coroner rules

Stanley Trevor Deakin, aged 82, of Brambles Residential Home on Birchfield Road, was exposed to asbestos during his working life and developed mesothelioma. An inquest held by Worcestershire Coroner’s Service opened on Monday, April 25 and closed on Tuesday, July 12, ruled Mr Godfrey died as the result of an industrial disease.

ONCOS-102 Mesothelioma Clinical Trial Promises Hope

Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases. The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses. Researchers are administering the immunotherapy drug as first-line therapy in combination with…

The post ONCOS-102 Mesothelioma Clinical Trial Promises Hope appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

ONCOS-102 Mesothelioma Clinical Trial Promises Hope

Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases. The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses. Researchers are administering the immunotherapy drug as first-line therapy in combination with…

The post ONCOS-102 Mesothelioma Clinical Trial Promises Hope appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

ONCOS-102 Mesothelioma Clinical Trial Promises Hope

Scandinavian-based Targovax launched the latest immunotherapy clinical trial for pleural mesothelioma, hoping it delivers a better way to treat patients with asbestos-related diseases. The randomized phase Ib/II trial evaluates the performance of ONCOS-102, an engineered human adenovirus designed to induce systemic, anti-tumor responses. Researchers are administering the immunotherapy drug as first-line therapy in combination with…

The post ONCOS-102 Mesothelioma Clinical Trial Promises Hope appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.